Thomas Powles MBBS, MRCP, MD

Articles

Dr. Powles on the Rationale to Evaluate ctDNA in High-Risk Muscle-Invasive Bladder Cancer

December 22nd 2020

Thomas Powles, MBBS, MRCP, MD, discusses the rationale to evaluate circulating tumor DNA in high-risk muscle-invasive bladder cancer.

Dr. Powles on the Role of ctDNA Positivity in High-Risk Muscle-Invasive Urothelial Cancer

December 15th 2020

Thomas Powles, MBBS, MRCP, MD, discusses the role of circulating tumor DNA positivity in high-risk muscle-invasive urothelial cancer.

Dr. Powles on FDA Approval of Pembrolizumab Plus Axitinib in Advanced RCC

April 22nd 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the FDA approval of the combination of pembrolizumab (Keytruda) plus axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Dr. Powles on the Results of the KEYNOTE-426 Trial in mRCC

March 15th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the results of the KEYNOTE-426 trial in metastatic renal cell carcinoma (mRCC).

Dr. Powles on Rationale for KEYNOTE-426 in mRCC

March 11th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the rationale for the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Dr. Powles on Potential With Durvalumab in Papillary RCC

February 17th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses durvalumab in combination with a MET inhibitor in the treatment of patients with papillary renal cancer.

Dr. Powles on the Current State of Research in Bladder Cancer

December 1st 2018

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses the current state of research in bladder cancer.

Dr. Powles on Biomarkers for Immunotherapy in Bladder Cancer

November 14th 2018

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses biomarkers for immunotherapy in bladder cancer.